Condition: Carcinoma, Renal Cell

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

A Study of Pembrolizumab in Combination With Belzutifan and Lenvatinib, or Pembrolizumab/Quavonlimab in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma

October 9, 2022

By clique_admin

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line Renal Cell Carcinoma

October 9, 2022

By clique_admin

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus Renal Cell Carcinoma

October 9, 2022

By clique_admin

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy